Payment overview · 2025
General Payments
$1,157.95
40 reported records · 14 companies
Healthcare provider profile · identity verified
David Gerard Provaznik, DO
Allopathic & Osteopathic Physicians|Family Medicine · WHEELERSBURG, OH · NPI 1245267624
Verified facts
What the public records show
CMS Open Payments records show David Gerard Provaznik, DO received $1,157.95 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Farxiga, Jardiance, Rexulti, Trelegy Ellipta, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 547 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 592 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 547 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 592 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Xifaxan by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $615.63 | 53.2% | 16 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $121.60 | 10.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $105.36 | 9.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.73 | 5.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.44 | 4.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.14 | 4.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.91 | 2.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.21 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.61 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.60 | 1.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.38 | 1.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.38 | 1.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.68 | 1.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.28 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,112.95 | 39 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $305.76 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $261.51 | 9 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $121.60 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $105.36 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $105.36 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $50.64 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.44 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.44 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.14 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 157 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 547 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 121 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
157 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
547 | 54 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
592 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
547 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
39 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
592 | 62 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1474 | 283 |
| Potassium Chloride | Potassium Chloride | 848 | 123 |
| Lisinopril | Lisinopril | 793 | 152 |
| Furosemide | Furosemide | 775 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 760 | 114 |
| Gabapentin | Gabapentin | 722 | 103 |
| Metoprolol Tartrate | Metoprolol Tartrate | 687 | 118 |
| Omeprazole | Omeprazole | 646 | 110 |
| Eliquis | Apixaban | 592 | 62 |
| Jardiance | Empagliflozin | 547 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 534 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 506 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 503 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 484 | 96 |
| Metformin Hcl | Metformin Hcl | 483 | 93 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 453 | 66 |
| Carvedilol | Carvedilol | 448 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 429 | 83 |
| Sertraline Hcl | Sertraline Hcl | 417 | 68 |
| Divalproex Sodium | Divalproex Sodium | 355 | 50 |
| Losartan Potassium | Losartan Potassium | 311 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 300 | 43 |
| Sucralfate | Sucralfate | 285 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 279 | 43 |
| Tramadol Hcl | Tramadol Hcl | 270 | 50 |
| Trazodone Hcl | Trazodone Hcl | 269 | 38 |
| Lorazepam | Lorazepam | 264 | 48 |
| Buspirone Hcl | Buspirone Hcl | 258 | 43 |
| Famotidine | Famotidine | 244 | 47 |
| Olanzapine | Olanzapine | 238 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 237 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 88 |
| Mirtazapine | Mirtazapine | 229 | 46 |
| Simvastatin | Simvastatin | 224 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 222 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 216 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 207 | 29 |
| Alprazolam | Alprazolam | 205 | 28 |
| Donepezil Hcl | Donepezil Hcl | 205 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 40 |
| Montelukast Sodium | Montelukast Sodium | 187 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 185 | 40 |
| Lactulose | Lactulose | 183 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 173 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 166 | 34 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 164 | 36 |
| Levetiracetam | Levetiracetam | 162 | 24 |
| Xarelto | Rivaroxaban | 161 | 23 |
| Ozempic | Semaglutide | 159 | 27 |
| Farxiga | Dapagliflozin Propanediol | 157 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 156 | 23 |
| Risperidone | Risperidone | 141 | 17 |
| Nifedipine Er | Nifedipine | 140 | 27 |
| Pregabalin | Pregabalin | 140 | 21 |
| Spironolactone | Spironolactone | 139 | 25 |
| Clonazepam | Clonazepam | 137 | 20 |
| Meloxicam | Meloxicam | 131 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 119 | 21 |
| Doxepin Hcl | Doxepin Hcl | 118 | 16 |
| Ibuprofen | Ibuprofen | 118 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 19 |
| Memantine Hcl | Memantine Hcl | 115 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 115 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 112 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 109 | 37 |
| Baclofen | Baclofen | 106 | 16 |
| Ondansetron Odt | Ondansetron | 105 | 31 |
| Celecoxib | Celecoxib | 103 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 99 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 98 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 18 |
| Lamotrigine | Lamotrigine | 98 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 96 | 16 |
| Glipizide | Glipizide | 95 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 91 | 19 |
| Linzess | Linaclotide | 91 | 17 |
| Clonidine Hcl | Clonidine Hcl | 89 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 16 |
| Ezetimibe | Ezetimibe | 88 | 16 |
| Januvia | Sitagliptin Phosphate | 88 | 11 |
| Azithromycin | Azithromycin | 85 | 68 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 16 |
| Finasteride | Finasteride | 78 | 12 |
| Allopurinol | Allopurinol | 77 | 18 |
| Cimetidine | Cimetidine | 77 | 18 |
| Novolog Flexpen | Insulin Aspart | 77 | 14 |
| Promethazine Hcl | Promethazine Hcl | 77 | 12 |
| Glimepiride | Glimepiride | 75 | 14 |
| Nitroglycerin | Nitroglycerin | 75 | 48 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 14 |
| Trulicity | Dulaglutide | 75 | 13 |
| Warfarin Sodium | Warfarin Sodium | 75 | 13 |
| Haloperidol Decanoate | Haloperidol Decanoate | 72 | suppressed |
| Myrbetriq | Mirabegron | 72 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | 15 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 71 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 69 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 65 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | suppressed |
| Prednisone | Prednisone | 61 | 25 |
| Latanoprost | Latanoprost | 60 | suppressed |
| Estradiol | Estradiol | 59 | suppressed |
| Haloperidol | Haloperidol | 58 | 12 |
| Nystatin | Nystatin | 58 | 22 |
| Aripiprazole | Aripiprazole | 57 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 57 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 12 |
| Lansoprazole | Lansoprazole | 54 | suppressed |
| Primidone | Primidone | 53 | suppressed |
| Tradjenta | Linagliptin | 53 | suppressed |
| Klor-Con M20 | Potassium Chloride | 52 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 13 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 51 | 13 |
| Invega Sustenna | Paliperidone Palmitate | 50 | suppressed |
| Movantik | Naloxegol Oxalate | 50 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Brilinta | Ticagrelor | 47 | suppressed |
| Bumetanide | Bumetanide | 47 | suppressed |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Methocarbamol | Methocarbamol | 47 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 45 | suppressed |
| Lubiprostone | Lubiprostone | 44 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Ranolazine Er | Ranolazine | 44 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Carbamazepine | Carbamazepine | 43 | suppressed |
| Torsemide | Torsemide | 43 | suppressed |
| Xifaxan | Rifaximin | 43 | suppressed |
| Lidocaine | Lidocaine | 42 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 41 | 11 |
| Austedo Xr | Deutetrabenazine | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | 14 |
| Methylprednisolone | Methylprednisolone | 40 | 30 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 39 | 38 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Irbesartan | Irbesartan | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 17 |
| Atenolol | Atenolol | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | 15 |
| Valsartan | Valsartan | 35 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 33 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 23 |
| Nabumetone | Nabumetone | 31 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 30 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 30 | suppressed |
| Oxazepam | Oxazepam | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 16 |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 22 |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 22 |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Naproxen | Naproxen | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Valproic Acid | Valproic Acid | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 15 |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Calcium Acetate | Calcium Acetate | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | 11 |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | 11 |
| Dutasteride | Dutasteride | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 12 |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 15 |
| Mesalamine | Mesalamine | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Nifedipine | Nifedipine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Belsomra | Suvorexant | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Combigan | Brimonidine Tartrate/Timolol | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Dupixent Syringe | Dupilumab | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Novolog | Insulin Aspart | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Acetic Acid | Acetic Acid | 18 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Entacapone | Entacapone | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 18 | suppressed |
| Methazolamide | Methazolamide | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Klayesta | Nystatin | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Nyamyc | Nystatin | 16 | 12 |
| Perphenazine | Perphenazine | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Dronabinol | Dronabinol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,157.95 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, FANAPT, FARXIGA, HETLIOZ, JARDIANCE, JOURNAVX, LYBALVI, NURTEC ODT, OTEZLA, Ohtuvayre, REPATHA, REXULTI, TRELEGY ELLIPTA, XIFAXAN, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error